Compare

Sanofi/$SNY

1D1W1M3M6MYTD1Y5YMAX

About Sanofi

Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest-revenue product, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
Ticker
$SNY
Sector
Health
Primary listing
NASDAQ
Employees
74,846
Headquarters
Paris, France
Website
www.sanofi.com

Sanofi Metrics

BasicAdvanced
$97B
11.07
$3.67
0.28
$1.76
4.35%

What the Analysts think about Sanofi

Analyst ratings (Buy, Hold, Sell) for Sanofi stock.
Analyst projections of the future price of Sanofi stock.

Bulls say / Bears say

Dupixent remains a powerful growth engine: second-quarter sales rose 37.6% to €5.2 billion, with strong demand across its approved uses. Sanofi raised its 2026 sales-growth outlook to around 10%. (Sanofi)
Growth is also coming from newer medicines: Sanofi’s pharma launches grew 48.3% in the second quarter, led by products including Ayvakit, ALTUVIIIO and Sarclisa. That gives the company another source of expansion alongside Dupixent. (Sanofi)
Sanofi and Regeneron have expanded their alliance to develop four next-generation antibodies, with Sanofi leading global sales if they reach market. The early-stage programmes could build on the companies’ immunology expertise and broaden Sanofi’s future product base. (Sanofi)
Sanofi remains heavily reliant on Dupixent, which accounted for 36% of 2025 sales, and its key US patent expires in 2031. That leaves the company needing new medicines to offset a major future loss of exclusivity. (Reuters, Reuters)
Recent setbacks have weakened confidence in Sanofi’s pipeline: the company stopped development of amlitelimab for atopic dermatitis and halted a Phase 3 study of riliprubart after an interim review found it unlikely to work well enough. These failures reduce potential successors to its blockbuster medicines. (Sanofi, Sanofi)
The strength of the latest quarter may be hard to sustain: management expects growth to normalise in the second half, while second-quarter business EPS growth was helped by one-off items. US Dupixent sales also benefited from a favourable adjustment to deductions, which may not recur. (Sanofi)
Data summarised monthly by Lightyear AI. Last updated on 14 Oct 2026.

Sanofi Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

Sanofi Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

Sanofi News

AllArticlesVideos

EU Accepts Sanofi's Concessions to Settle Antitrust Probe Over Vaccine Marketing

WSJ4 days ago

As First Dupixent MDL Hearing Opens, Weitz & Luxenberg Points to Sanofi's Own Words on a Cancer That Hides Behind Eczema

Business Wire2 weeks ago

Regeneron, Sanofi Expand Alliance in Deal Worth Up to $8 Billion

MarketBeat2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.